leftflash
A Potent New Force Introducing DORIBAX
DORIBAX is indicated for adults in the treatment of complicated intra-abdominal infections* and complicated urinary tract infections, including pyelonephritis
  • Excellent gram-positive and gram-negative and anaerobic coverage
  • Demonstrated safety and tolerability profiles—no seizures reported in 4 large Phase III clinical trials

Carbapenem potency that breaks through today's gram-negative pathogens‡1-3
  • Proven in vitro activity vs P aeruginosa, Enterobacteriaceae, and Acinetobacter1-3
  • Low propensity to select for in vitro resistance in P aeruginosa4,5
  • The molecular structure of DORIBAX may confer a high level of in vitro activity vs a wide range of pathogens6
*Caused by susceptible strains of E coli, K pneumoniae, P aeruginosa, B caccae, B fragilis, B thetaiotamicron, B uniformis, B vulgatus, S intermedius, S constellatus, or P micros.

Caused by susceptible strains of E coli, including cases with concurrent bacteremia, K pneumoniae, P mirabilis, P aeruginosa, or A baumannii.

In vitro activity does not necessarily correlate with clinical results.

Please see Important Safety Information Below


REFERENCES
carbapenem_potencycarbapenem_potencyregister
bottombar